Journal ArticleOPEN ACCESS

Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide

  • Lee J
  • Choi J
  • Kwon K
  • et al.
The Korean Journal of Hematology (2010) 45(2) 102
DOI: 10.5045/kjh.2010.45.2.102
N/ACitations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

A combination of busulfan (Bu) and cyclophosphamide (Cy) has been used as a standard myeloablative regimen for allogeneic hematopoietic stem cell transplantation (HSCT). Recent studies postulate that fludarabine (Flu) is a less toxic substitute for Cy.

Cite

CITATION STYLE

APA

Lee, J. H., Choi, J., Kwon, K. A., Lee, S., Oh, S. Y., Kwon, H.-C., … Kim, S.-H. (2010). Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide. The Korean Journal of Hematology, 45(2), 102. https://doi.org/10.5045/kjh.2010.45.2.102

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free